[
    [
        {
            "time": "",
            "orginal_text": "恒瑞医药CEO周云曙辞职：孙飘扬再出山已失A股医药一哥宝座",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "周云曙",
                    "辞职",
                    "孙飘扬",
                    "A股",
                    "医药"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "恒瑞医药CEO周云曙辞职：孙飘扬再出山已失A股医药一哥宝座",
            "scores": {
                "News_content": "恒瑞医药CEO周云曙辞职：孙飘扬再出山已失A股医药一哥宝座",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "孙飘扬回归，医药江湖拭目以待",
            "features": {
                "keywords": [
                    "孙飘扬",
                    "回归",
                    "医药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "孙飘扬回归，医药江湖拭目以待",
            "scores": {
                "News_content": "孙飘扬回归，医药江湖拭目以待",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "北向资金今日净买入16.42亿元，新能源股表现分化",
            "features": {
                "keywords": [
                    "北向资金",
                    "净买入",
                    "新能源"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "北向资金今日净买入16.42亿元，新能源股表现分化",
            "scores": {
                "News_content": "北向资金今日净买入16.42亿元，新能源股表现分化",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "百济神州靠上市输血，这是创新药企的真出路吗",
            "features": {
                "keywords": [
                    "百济神州",
                    "上市",
                    "创新药企"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "百济神州靠上市输血，这是创新药企的真出路吗",
            "scores": {
                "News_content": "百济神州靠上市输血，这是创新药企的真出路吗",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业一周观察：板块大幅调整 如何看待创新药和CXO的未来",
            "features": {
                "keywords": [
                    "医药行业",
                    "板块调整",
                    "创新药",
                    "CXO"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医药行业一周观察：板块大幅调整 如何看待创新药和CXO的未来",
            "scores": {
                "News_content": "医药行业一周观察：板块大幅调整 如何看待创新药和CXO的未来",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "财经药点｜上半年国内上市药企市值Top20揭晓，两制药龙头市值一升一降",
            "features": {
                "keywords": [
                    "药企",
                    "市值",
                    "制药龙头"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "original_text": "财经药点｜上半年国内上市药企市值Top20揭晓，两制药龙头市值一升一降",
            "scores": {
                "News_content": "财经药点｜上半年国内上市药企市值Top20揭晓，两制药龙头市值一升一降",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
            "features": {
                "keywords": [
                    "CRO",
                    "概念",
                    "新政",
                    "资源",
                    "利好"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
            "scores": {
                "News_content": "CRO概念持续回暖，机构：新政释放资源，利好行业长期发展",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业周报：CDE发布临床研发指导原则 加速创新药及CXO行业结构化进程",
            "features": {
                "keywords": [
                    "医药行业",
                    "CDE",
                    "临床研发",
                    "创新药",
                    "CXO"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药行业周报：CDE发布临床研发指导原则 加速创新药及CXO行业结构化进程",
            "scores": {
                "News_content": "医药行业周报：CDE发布临床研发指导原则 加速创新药及CXO行业结构化进程",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "创新研发步入收获期，新规之下恒瑞机会何在？",
            "features": {
                "keywords": [
                    "创新研发",
                    "恒瑞",
                    "新规"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "创新研发步入收获期，新规之下恒瑞机会何在？",
            "scores": {
                "News_content": "创新研发步入收获期，新规之下恒瑞机会何在？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "市值蒸发2000亿，63岁创始人孙飘扬复出，恒瑞能否力挽狂澜？",
            "features": {
                "keywords": [
                    "市值蒸发",
                    "孙飘扬",
                    "复出",
                    "恒瑞"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "市值蒸发2000亿，63岁创始人孙飘扬复出，恒瑞能否力挽狂澜？",
            "scores": {
                "News_content": "市值蒸发2000亿，63岁创始人孙飘扬复出，恒瑞能否力挽狂澜？",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业：十四五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
            "features": {
                "keywords": [
                    "医药生物",
                    "十四五",
                    "血制品",
                    "天坛生物",
                    "博雅生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业：十四五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
            "scores": {
                "News_content": "医药生物行业：十四五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "A股融资融券日报：两融余额增加20.08亿元（7月9日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股融资融券日报：两融余额增加20.08亿元（7月9日）",
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加20.08亿元（7月9日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "每日理财观察：央行全面降准0.5个百分点，释放资金约1万亿",
            "features": {
                "keywords": [
                    "央行",
                    "降准",
                    "资金释放"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "每日理财观察：央行全面降准0.5个百分点，释放资金约1万亿",
            "scores": {
                "News_content": "每日理财观察：央行全面降准0.5个百分点，释放资金约1万亿",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "股价持续下跌 恒瑞医药或面临技术性调整",
            "features": {
                "keywords": [
                    "股价下跌",
                    "恒瑞医药",
                    "技术性调整"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "股价持续下跌 恒瑞医药或面临技术性调整",
            "scores": {
                "News_content": "股价持续下跌 恒瑞医药或面临技术性调整",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药市值掉队半年蒸发2257亿 周云曙抱恙归隐63岁孙飘扬“负重”出山",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "市值蒸发",
                    "周云曙",
                    "孙飘扬"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "恒瑞医药市值掉队半年蒸发2257亿 周云曙抱恙归隐63岁孙飘扬“负重”出山",
            "scores": {
                "News_content": "恒瑞医药市值掉队半年蒸发2257亿 周云曙抱恙归隐63岁孙飘扬“负重”出山",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药换帅：浅谈10年的8个创新药（2011-2021）",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "换帅",
                    "创新药"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "恒瑞医药换帅：浅谈10年的8个创新药（2011-2021）",
            "scores": {
                "News_content": "恒瑞医药换帅：浅谈10年的8个创新药（2011-2021）",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "董事长辞职恒瑞医药“换帅” 创始人再复出",
            "features": {
                "keywords": [
                    "董事长辞职",
                    "恒瑞医药",
                    "换帅",
                    "创始人复出"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "董事长辞职恒瑞医药“换帅” 创始人再复出",
            "scores": {
                "News_content": "董事长辞职恒瑞医药“换帅” 创始人再复出",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]